SenesTech, Inc. (SNES): Price and Financial Metrics
GET POWR RATINGS... FREE!
SNES POWR Grades
- SNES scores best on the Momentum dimension, with a Momentum rank ahead of 66.65% of US stocks.
- SNES's strongest trending metric is Value; it's been moving up over the last 198 days.
- SNES's current lowest rank is in the Stability metric (where it is better than 1.54% of US stocks).
SNES Stock Summary
- SenesTech Inc's market capitalization of $18,975,912 is ahead of only 3.65% of US-listed equities.
- With a price/sales ratio of 67.29, SenesTech Inc has a higher such ratio than 95.54% of stocks in our set.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SNES comes in at -46.81% -- higher than that of just 5.02% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to SenesTech Inc are OBLN, TRUE, NURO, NEPT, and INDO.
- Visit SNES's SEC page to see the company's official filings. To visit the company's web site, go to www.senestech.com.
SNES Stock Price Chart Interactive Chart >
SNES Price/Volume Stats
|Current price||$1.56||52-week high||$3.36|
|Prev. close||$1.52||52-week low||$1.30|
|Day high||$1.66||Avg. volume||1,768,360|
|50-day MA||$1.69||Dividend yield||N/A|
|200-day MA||$1.72||Market Cap||7.96M|
SenesTech, Inc. (SNES) Company Bio
SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. It develops a pipeline of fertility control and animal health products, such as ContraPest, plant-based fertility control, feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment. The company was founded in 2004 and is based in Flagstaff, Arizona.
SNES Latest News Stream
|Loading, please wait...|
SNES Latest Social Stream
View Full SNES Social Stream
Latest SNES News From Around the Web
Below are the latest news stories about SenesTech Inc that investors may wish to consider to help them evaluate SNES as an investment opportunity.
Aptose Biosciences Inc (NASDAQ: APTO) shares are trading higher after the company reported fourth-quarter earnings results. Oppenheimer analyst Matthew Biegler also maintains Aptose with an Outperform and raises the price target from $8 to $9. Aptose is a biotechnology company. The company develops targeted medicines and personalized therapies for the precision treatment of life-threatening cancers such as acute myeloid leukemia, myelodysplastic syndromes and other hematologic malignancies and also therapies for Oncology. SenesTech Inc (NASDAQ: SNES) shares are trading higher after the company announced the initiation of a collaboration with Liphatech to develop a non-liquid formulation of ContraPest. SenesTech is a biotech platform and research company engaged in developing technology ...
SenesTech Announces Collaboration with Liphatech to Develop a New Non-Liquid Formulation of ContraPest®
SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary, next generation technologies for managing animal pest populations through fertility control, today announced the initiation of a collaboration with Liphatech, Inc., a global leader in the research, manufacturing and distribution of innovative pest control products, to develop a non-liquid formulation of ContraPest®. Both companies will be contributing resources to the project.
SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary, next generation technologies for managing animal pest populations through fertility control, announced today that it will present at the Lytham Partners Spring 2021 Investor Conference on Wednesday, March 31, 2021 at 12:30pm ET.
SenesTech, Inc. Announces Closing of $3.95 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules
PHOENIX, March 23, 2021 (GLOBE NEWSWIRE) -- SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary, next generation technologies for managing animal pest populations through fertility control, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 1,975,000 shares of its common stock at a purchase price of $2.00 per share for gross proceeds of $3.95 million. SenesTech intends to use net proceeds from the registered direct offering for working capital and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. A shelf registration statement on Form S-3 (File No. 333-225712) relating to the registered direct offering of the shares of common stock described above wa...
SenesTech Announces Successful Completion of a Long Term Study of an Urban Deployment of ContraPest®
SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary, next generation technologies for managing animal pest populations through fertility control, today announced the results of a long-term study of a deployment of ContraPest® in a large, east coast urban setting, with demonstrated, sustained success in reducing rat populations.
SNES Price Returns